Immunodiagnostics firm Oncimmune has reported positive results from a randomised clinical trial, ECLS, which assessed its EarlyCDT Lung cancer detection test.
EarlyCDT Lung uses the company’s technology, which detects the presence of autoantibodies produced by the immune system against cancer cells.
The test is intended to identify lung cancer and to classify individuals depending on the cancer risk.
Conducted in 12,209 people who were at high risk of developing lung cancer in Scotland, the ECLS trial demonstrated the test’s ability to decrease the late-stage cancer incidence at diagnosis.
In comparison with standard clinical practice in the UK, EarlyCDT Lung helped to diagnose more people at an early stage of their cancer in two years following the test.
According to the study results, 41.1% of individuals who took the EarlyCDT Lung test and went on to develop cancer in the next years were diagnosed prematurely, versus 26.8% of those who received the standard diagnosis.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Oncimmune said that its test led to a 36% decrease in late-stage incidence after two years of follow up.
During the study, an X-ray and computerised tomography (CT) scan followed a positive EarlyCDT Lung test result.
Oncimmune CEO Adam Hill said: “We are thrilled that the ECLS trial has demonstrated so clearly the potential of our EarlyCDT technology platform to transform the way cancer is diagnosed.
“We look forward to working with health authorities in Scotland and beyond to roll out EarlyCDT Lung more widely, with the aim of saving lives and reducing costs for the NHS and other healthcare systems around the world.”
The company is planning to test the study in a larger population of up to 200,000 patients. It will take place in a natural environment, to determine its effect on survival and mortality.
Furthermore, Oncimmune intends to expand the application of its technology to other cancer types, such as liver, ovarian, breast and prostate cancers.